treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel,<sup>2</sup> solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.3

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission. Issued: May 2, 2022.

#### Lisa Barton,

Secretary to the Commission.

[FR Doc. 2022-09755 Filed 5-5-22; 8:45 am]

BILLING CODE 7020-02-P

## **DEPARTMENT OF JUSTICE**

### **Drug Enforcement Administration**

[Docket No. DEA-991]

Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals Inc.

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Patheon Pharmaceuticals Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTAL INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration

on or before July 5, 2022. Such persons may also file a written request for a hearing on the application on or before July 5, 2022.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.'

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on February 3, 2022, Patheon Pharmaceuticals Inc., 2110 East Galbraith Road, Cincinnati, Ohio 45237–1625, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	2010	I

The company plans to manufacture the above-listed controlled substance as Active Pharmaceutical Ingredient (API) that will be further synthesized into Food and Drug Administration-approved dosage forms. No other activities for this drug code are authorized for this registration.

## Matthew J. Strait,

Deputy Assistant Administrator. [FR Doc. 2022–09779 Filed 5–5–22; 8:45 am]

BILLING CODE P

#### **DEPARTMENT OF JUSTICE**

[OMB 1140-0066]

Agency Information Collection
Activities; Proposed eCollection of
eComments Requested; Manufacturers
of Ammunition, Records and
Supporting Data of Ammunition
Manufactured and Disposed of

**AGENCY:** Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.

**ACTION:** 60-Day notice.

SUMMARY: The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), Department of Justice (DOJ), will submit the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection (IC) is also being published to obtain comments from the public and affected agencies.

**DATES:** Comments are encouraged and will be accepted for 60 days until July 5, 2022.

FOR FURTHER INFORMATION CONTACT: If you have additional comments regarding the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions, or additional information, contact: Jason Gluck, Firearms Industry Programs Branch, Firearms Explosives Industries Division, Enforcement Programs Services, by mail at 99 New York Ave. NE, Washington, DC 20226, by email at FIPB-informationcollection@atf.gov, or telephone at 202–648–7190.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- —Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- —Evaluate whether and, if so, how the quality, utility, and clarity of the information to be collected can be enhanced; and
- —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

# Overview of This Information Collection

1. Type of Information Collection (check justification or form 83): Extension without Change of a Currently Approved Collection.

 $<sup>^2\,\</sup>mathrm{All}$  contract personnel will sign appropriate nondisclosure agreements.

<sup>&</sup>lt;sup>3</sup> Electronic Document Information System (EDIS): https://edis.usitc.gov.